Participant Flow Chart



Baseline Characteristics

	Tota
	(N=10
Sex	
Male	10 (100%
Ν	1
Race	
White	10 (100%
Ν	1
Age	
Ν	1
Mean	32
SD	7.9
Median	32
Min	2
Max	2
Height (m)	
Ν	1
Mean	1
SD	0.0
Median	1.7
Min	1.6
Max	1.8
Weight(kg)	
Ν	
Mean	82
SD	10.3
Median	83.7
Min	66
Max	96
BMI (kg/m2)	
Ν	1
Mean	26
SD	3.4
Median	27.5
Min	21.6
Max	29.9

Outcomes Measured

	Treatment A	Treatment B	Treatment C	
	(N=10)	(N=10)	(N=10)	
Site of Onset with the gastrointestinal tract				
Stomach	7 (70%)	0 (0%)	2 (20%)	
Small Intestine	3 (30%)	2 (20%)	4 (40%	
Colon	0 (0%)	7 (70%)	3 (30%)	
Not Observed	0 (0%)	1 (10%)	1 (10%)	
Ν	10	10	10	
Onset radiolabel release [min]				
Mean	30	510.8	229.2	
SD	10.6	159.3	209	
Median	22.5	532.5	142.5	
Min - Max	22.5 – 52.5	217.5 - 712.5	37.5 – 622.5	
Ν	10	9	9	

Adverse Events

Total Subjects n = 10	Pre- Treatment	Treatment A	Treatment B	Treatment C	Total			
Number of subjects with at least one AE	1 (10%)	3 (30%)	1 (10%)	3 (30%)	5 (50%)			
Total number of AEs	1	5	1	4	11			
Total number of subjects with at least one SAE	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			
Total number of SAEs	0	0	0	0	0			
Total AEs n = 11								
Any treatment emergent AEs felt related to study product	0 (0%)	3 (27.3%)	1 (9.1%)	3 (27.3%)	7 (63.6%)			
Any AEs leading to death	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			
Any AEs leading to discontinuation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)			